Bonviva injection for injection 3mg / 3ml №1 syringe tube


More info

Bonviva injection solution 3mg / 3ml No. 1 syringe tube


Hypersensitivity to ibandronic acid or other components of the drug. Hypocalcemia. Prior to starting Bonviva, as well as the appointment of all bisphosphonates used to treat osteoporosis, hypocalcemia should be eliminated. Severe renal dysfunction (serum creatinine> 200 mcmol / L (2.3 mg / dL) or creatinine clearance <30 ml / min). Pregnancy and lactation period. Pregnancy and lactation period

special instructions

Side effects:

Bonviva, like other bisphosphonates, when administered intravenously may cause a short-term decrease in serum calcium levels.
Gastrointestinal (GI): dyspepsia (nausea, abdominal pain, flatulence), diarrhea, constipation, gastritis, gastroenteritis.
On the part of the musculoskeletal system: arthralgia, myalgia, pain in the limbs and bones, osteoarthritis.
On the part of the nervous system and mental sphere: headache, dizziness, insomnia, depression.
From the skin and its appendages: rash.
The body as a whole: flu-like syndrome, weakness, reactions at the injection site, phlebitis, thrombophlebitis, nasopharyngitis, cystitis, urinary tract infections, bronchitis, upper respiratory tract infections, arterial hypertension, hypercholesterolemia, uveitis, scleritis.
Hypersensitivity reactions: angioedema, urticaria.

During preclinical studies, no signs of direct embryotoxic or teratogenic action were found. The adverse effects of ibandronic acid in reproductive toxicity studies in animals were the same as in all bisphosphonates — reducing the number of embryos, disrupting the process of childbirth, and increasing the frequency of visceral abnormalities (narrowing of the pelvic-ureteral segment).

Bonviva is incompatible with calcium-containing solutions and other solutions for intravenous administration.

It is a pharmaceutical drug. Use only as directed by your doctor.

Mode of application

Drug for intravenous use only! It is entered only by the expert. It should be avoided if it is intraarterially injected or released into the surrounding tissue.Before the introduction, it is necessary to inspect the solution for the absence of impurities or discoloration. Use needles complete with syringe tubes. The syringe tube is intended for single injection only.